Insulin-like growth factors I and II peptide and messenger RNA levels in macrosomic infants of diabetic pregnancies

Steven Roth, Mary Pell Abernathy, Wei Hua Lee, Linda Pratt, Scott Denne, Alan Golichowski, Ora Hirsch Pescovitz

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

Objective: Fetal macrosomia is a common complication of maternal diabetes mellitus and is associated with substantial morbidity, but the precise cellular and molecular mechanisms that induce fetal macrosomia are not well understood. We hypothesized that the macrosomia or accelerated fetal growth seen in infants of diabetic mothers is due to a perturbation of a putative placental-fetal growth axis involving growth hormone and insulin-like growth factors. Insulin-like growth factors I and II (IGF-I and IGF-II) are ubiquitous peptides that share structural homology with insulin and have been implicated in processes that control fetal growth. Studies of IGF levels in pregnancies complicated by diabetes and macrosomia have shown conflicting results. We set out to resolve these inconsistencies using molecular techniques to measure the placental IGF-I and IGF-II messenger RNA levels in placentas and a specific radioimmunoassay to measure IGF-I and IGF-II peptide levels in cord serum of normal and diabetic pregnancies. Methods: Placentas and cord blood were collected immediately after delivery at term from patients from each of three study groups: 1) nonmacrosomic infants of nondiabetic mothers (controls), 2) macrosomic infants of diabetic mothers, and 3) nonmacrosomic infants of diabetic mothers. Both IGF-I and IGF-II levels were measured in cord serum and placental tissue by a specific radioimmunoassay. Total RNA was extracted and analyzed by Northern gels hybridized to IGF-I or IGF-II riboprobes. Results: Levels of IGF-I in cord serum from the macrosomic diabetic group (83 ± 4.2 ng/mL) were significantly higher than levels from either the nonmacrosomic nondiabetic group (38 ± 1.9 ng/mL) or the nonmacrosomic diabetic group (13 ± 3.5 ng/mL). There was a direct linear correlation between cord serum IGF-I and infant birth weight, independent of diabetes (r2 = 0.61, P < .01). On the other hand, IGF-II cord serum levels were elevated in diabetic pregnancies (337 ± 12.2 ng/mL) compared with nondiabetic women (172 ± 19.8 ng/mL), but there was no correlation with birth weight (r2 = 0.035, P = .52). In contrast to cord blood levels, IGF-II peptide levels were significantly decreased in the placentas from mothers with diabetes compared with nondiabetic controls (116 ± 3.2 versus 158 ± 5.3 ng/mL, respectively). Levels of IGF-I peptide in placentas from both nondiabetic controls and diabetic mothers were below the sensitivity of the assay. Levels of IGF-I and IGF-II mRNA did not differ in placentas from diabetic mothers versus nondiabetic controls. Conclusion: Cord serum IGF-II levels are elevated in diabetic pregnancies without a concomitant increase in placental IGF-II levels. This novel finding, combined with the finding that IGF-I levels are correlated with macrosomia independent of the diabetic state, contributes to our understanding of the possible mechanisms involved in fetal growth in pregnancies complicated by diabetes.

Original languageEnglish
Pages (from-to)78-84
Number of pages7
JournalJournal of the Society for Gynecologic Investigation
Volume3
Issue number2
DOIs
StatePublished - 1996

Fingerprint

Insulin-Like Growth Factor II
Insulin-Like Growth Factor I
Pregnancy
Messenger RNA
Peptides
Mothers
Pregnancy in Diabetics
Placenta
Fetal Development
Fetal Macrosomia
Serum
Fetal Blood
Birth Weight
Radioimmunoassay
Somatomedins
Diabetes Complications
Growth Hormone
Gels
RNA
Insulin

Keywords

  • Insulin-like growth factors
  • macrosomia
  • maternal diabetes

ASJC Scopus subject areas

  • Obstetrics and Gynecology

Cite this

Insulin-like growth factors I and II peptide and messenger RNA levels in macrosomic infants of diabetic pregnancies. / Roth, Steven; Abernathy, Mary Pell; Lee, Wei Hua; Pratt, Linda; Denne, Scott; Golichowski, Alan; Pescovitz, Ora Hirsch.

In: Journal of the Society for Gynecologic Investigation, Vol. 3, No. 2, 1996, p. 78-84.

Research output: Contribution to journalArticle

Roth, Steven ; Abernathy, Mary Pell ; Lee, Wei Hua ; Pratt, Linda ; Denne, Scott ; Golichowski, Alan ; Pescovitz, Ora Hirsch. / Insulin-like growth factors I and II peptide and messenger RNA levels in macrosomic infants of diabetic pregnancies. In: Journal of the Society for Gynecologic Investigation. 1996 ; Vol. 3, No. 2. pp. 78-84.
@article{ac33bf7421654483bafacbd6808cf6a4,
title = "Insulin-like growth factors I and II peptide and messenger RNA levels in macrosomic infants of diabetic pregnancies",
abstract = "Objective: Fetal macrosomia is a common complication of maternal diabetes mellitus and is associated with substantial morbidity, but the precise cellular and molecular mechanisms that induce fetal macrosomia are not well understood. We hypothesized that the macrosomia or accelerated fetal growth seen in infants of diabetic mothers is due to a perturbation of a putative placental-fetal growth axis involving growth hormone and insulin-like growth factors. Insulin-like growth factors I and II (IGF-I and IGF-II) are ubiquitous peptides that share structural homology with insulin and have been implicated in processes that control fetal growth. Studies of IGF levels in pregnancies complicated by diabetes and macrosomia have shown conflicting results. We set out to resolve these inconsistencies using molecular techniques to measure the placental IGF-I and IGF-II messenger RNA levels in placentas and a specific radioimmunoassay to measure IGF-I and IGF-II peptide levels in cord serum of normal and diabetic pregnancies. Methods: Placentas and cord blood were collected immediately after delivery at term from patients from each of three study groups: 1) nonmacrosomic infants of nondiabetic mothers (controls), 2) macrosomic infants of diabetic mothers, and 3) nonmacrosomic infants of diabetic mothers. Both IGF-I and IGF-II levels were measured in cord serum and placental tissue by a specific radioimmunoassay. Total RNA was extracted and analyzed by Northern gels hybridized to IGF-I or IGF-II riboprobes. Results: Levels of IGF-I in cord serum from the macrosomic diabetic group (83 ± 4.2 ng/mL) were significantly higher than levels from either the nonmacrosomic nondiabetic group (38 ± 1.9 ng/mL) or the nonmacrosomic diabetic group (13 ± 3.5 ng/mL). There was a direct linear correlation between cord serum IGF-I and infant birth weight, independent of diabetes (r2 = 0.61, P < .01). On the other hand, IGF-II cord serum levels were elevated in diabetic pregnancies (337 ± 12.2 ng/mL) compared with nondiabetic women (172 ± 19.8 ng/mL), but there was no correlation with birth weight (r2 = 0.035, P = .52). In contrast to cord blood levels, IGF-II peptide levels were significantly decreased in the placentas from mothers with diabetes compared with nondiabetic controls (116 ± 3.2 versus 158 ± 5.3 ng/mL, respectively). Levels of IGF-I peptide in placentas from both nondiabetic controls and diabetic mothers were below the sensitivity of the assay. Levels of IGF-I and IGF-II mRNA did not differ in placentas from diabetic mothers versus nondiabetic controls. Conclusion: Cord serum IGF-II levels are elevated in diabetic pregnancies without a concomitant increase in placental IGF-II levels. This novel finding, combined with the finding that IGF-I levels are correlated with macrosomia independent of the diabetic state, contributes to our understanding of the possible mechanisms involved in fetal growth in pregnancies complicated by diabetes.",
keywords = "Insulin-like growth factors, macrosomia, maternal diabetes",
author = "Steven Roth and Abernathy, {Mary Pell} and Lee, {Wei Hua} and Linda Pratt and Scott Denne and Alan Golichowski and Pescovitz, {Ora Hirsch}",
year = "1996",
doi = "10.1016/1071-5576(95)00048-8",
language = "English",
volume = "3",
pages = "78--84",
journal = "Reproductive Sciences",
issn = "1933-7191",
publisher = "SAGE Publications Inc.",
number = "2",

}

TY - JOUR

T1 - Insulin-like growth factors I and II peptide and messenger RNA levels in macrosomic infants of diabetic pregnancies

AU - Roth, Steven

AU - Abernathy, Mary Pell

AU - Lee, Wei Hua

AU - Pratt, Linda

AU - Denne, Scott

AU - Golichowski, Alan

AU - Pescovitz, Ora Hirsch

PY - 1996

Y1 - 1996

N2 - Objective: Fetal macrosomia is a common complication of maternal diabetes mellitus and is associated with substantial morbidity, but the precise cellular and molecular mechanisms that induce fetal macrosomia are not well understood. We hypothesized that the macrosomia or accelerated fetal growth seen in infants of diabetic mothers is due to a perturbation of a putative placental-fetal growth axis involving growth hormone and insulin-like growth factors. Insulin-like growth factors I and II (IGF-I and IGF-II) are ubiquitous peptides that share structural homology with insulin and have been implicated in processes that control fetal growth. Studies of IGF levels in pregnancies complicated by diabetes and macrosomia have shown conflicting results. We set out to resolve these inconsistencies using molecular techniques to measure the placental IGF-I and IGF-II messenger RNA levels in placentas and a specific radioimmunoassay to measure IGF-I and IGF-II peptide levels in cord serum of normal and diabetic pregnancies. Methods: Placentas and cord blood were collected immediately after delivery at term from patients from each of three study groups: 1) nonmacrosomic infants of nondiabetic mothers (controls), 2) macrosomic infants of diabetic mothers, and 3) nonmacrosomic infants of diabetic mothers. Both IGF-I and IGF-II levels were measured in cord serum and placental tissue by a specific radioimmunoassay. Total RNA was extracted and analyzed by Northern gels hybridized to IGF-I or IGF-II riboprobes. Results: Levels of IGF-I in cord serum from the macrosomic diabetic group (83 ± 4.2 ng/mL) were significantly higher than levels from either the nonmacrosomic nondiabetic group (38 ± 1.9 ng/mL) or the nonmacrosomic diabetic group (13 ± 3.5 ng/mL). There was a direct linear correlation between cord serum IGF-I and infant birth weight, independent of diabetes (r2 = 0.61, P < .01). On the other hand, IGF-II cord serum levels were elevated in diabetic pregnancies (337 ± 12.2 ng/mL) compared with nondiabetic women (172 ± 19.8 ng/mL), but there was no correlation with birth weight (r2 = 0.035, P = .52). In contrast to cord blood levels, IGF-II peptide levels were significantly decreased in the placentas from mothers with diabetes compared with nondiabetic controls (116 ± 3.2 versus 158 ± 5.3 ng/mL, respectively). Levels of IGF-I peptide in placentas from both nondiabetic controls and diabetic mothers were below the sensitivity of the assay. Levels of IGF-I and IGF-II mRNA did not differ in placentas from diabetic mothers versus nondiabetic controls. Conclusion: Cord serum IGF-II levels are elevated in diabetic pregnancies without a concomitant increase in placental IGF-II levels. This novel finding, combined with the finding that IGF-I levels are correlated with macrosomia independent of the diabetic state, contributes to our understanding of the possible mechanisms involved in fetal growth in pregnancies complicated by diabetes.

AB - Objective: Fetal macrosomia is a common complication of maternal diabetes mellitus and is associated with substantial morbidity, but the precise cellular and molecular mechanisms that induce fetal macrosomia are not well understood. We hypothesized that the macrosomia or accelerated fetal growth seen in infants of diabetic mothers is due to a perturbation of a putative placental-fetal growth axis involving growth hormone and insulin-like growth factors. Insulin-like growth factors I and II (IGF-I and IGF-II) are ubiquitous peptides that share structural homology with insulin and have been implicated in processes that control fetal growth. Studies of IGF levels in pregnancies complicated by diabetes and macrosomia have shown conflicting results. We set out to resolve these inconsistencies using molecular techniques to measure the placental IGF-I and IGF-II messenger RNA levels in placentas and a specific radioimmunoassay to measure IGF-I and IGF-II peptide levels in cord serum of normal and diabetic pregnancies. Methods: Placentas and cord blood were collected immediately after delivery at term from patients from each of three study groups: 1) nonmacrosomic infants of nondiabetic mothers (controls), 2) macrosomic infants of diabetic mothers, and 3) nonmacrosomic infants of diabetic mothers. Both IGF-I and IGF-II levels were measured in cord serum and placental tissue by a specific radioimmunoassay. Total RNA was extracted and analyzed by Northern gels hybridized to IGF-I or IGF-II riboprobes. Results: Levels of IGF-I in cord serum from the macrosomic diabetic group (83 ± 4.2 ng/mL) were significantly higher than levels from either the nonmacrosomic nondiabetic group (38 ± 1.9 ng/mL) or the nonmacrosomic diabetic group (13 ± 3.5 ng/mL). There was a direct linear correlation between cord serum IGF-I and infant birth weight, independent of diabetes (r2 = 0.61, P < .01). On the other hand, IGF-II cord serum levels were elevated in diabetic pregnancies (337 ± 12.2 ng/mL) compared with nondiabetic women (172 ± 19.8 ng/mL), but there was no correlation with birth weight (r2 = 0.035, P = .52). In contrast to cord blood levels, IGF-II peptide levels were significantly decreased in the placentas from mothers with diabetes compared with nondiabetic controls (116 ± 3.2 versus 158 ± 5.3 ng/mL, respectively). Levels of IGF-I peptide in placentas from both nondiabetic controls and diabetic mothers were below the sensitivity of the assay. Levels of IGF-I and IGF-II mRNA did not differ in placentas from diabetic mothers versus nondiabetic controls. Conclusion: Cord serum IGF-II levels are elevated in diabetic pregnancies without a concomitant increase in placental IGF-II levels. This novel finding, combined with the finding that IGF-I levels are correlated with macrosomia independent of the diabetic state, contributes to our understanding of the possible mechanisms involved in fetal growth in pregnancies complicated by diabetes.

KW - Insulin-like growth factors

KW - macrosomia

KW - maternal diabetes

UR - http://www.scopus.com/inward/record.url?scp=0030027014&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030027014&partnerID=8YFLogxK

U2 - 10.1016/1071-5576(95)00048-8

DO - 10.1016/1071-5576(95)00048-8

M3 - Article

C2 - 8796812

AN - SCOPUS:0030027014

VL - 3

SP - 78

EP - 84

JO - Reproductive Sciences

JF - Reproductive Sciences

SN - 1933-7191

IS - 2

ER -